Benzinga's Top Pre-Market Losers

Neurocrine Biosciences

shares dropped 27.25% to $12.15 in pre-market trading after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of tardive dyskinesia. ChemoCentryx

dipped 15.25% to $7 in the pre-market session after the company announced top-line interim results for CCX140 in an ongoing Phase II trial. HD Supply Holdings

dipped 8.68% to $22.60 in the pre-market session on Q2 results. Urban Outfitters

shares fell 6.58% to $39.90 in the pre-market trading. William Blair cut its Q3 earnings view for Urban Outfitters to 45c.